Skip to main content

Table 2 Risk factors for survival in patients with HIV-associated Burkitt lymphoma

From: Clinical characteristics and outcomes of newly diagnosed patients with human immunodeficiency virus-associated Burkitt lymphoma: the Central and Western China AIDS lymphoma league 002 study (CALL-002 study)

 

Overall survival

Progression-free survival

Variables

Univariate

Multivariate

Univariate

Multivariate

 

P value

HR

95%

P* value

P value

HR

95%

P* value

Male

0.941

   

0.826

   

Age > 40

0.077

   

0.277

   

Household registration

0.249

   

0.417

   

Primary site

0.668

   

0.999

   

Evaluated LDH

0.889

   

0.291

   

LDH > 3ULN

0.041

2.806

1.050–7.497

0.040

0.108

   

ECOG > 1

0.872

   

0.851

   

With B symptom

0.247

   

0.308

   

Ann Arbor stage III-IV

0.835

   

0.140

   

BM involvement

0.397

   

0.539

   

CNS involvement

< 0.001

5.572

2.019–15.375

0.001

< 0.001

5.985

2.165–16.542

0.001

CD4 > 100 cells/μl

0.302

   

0.522

   

HIV plasmaviremia

0.159

   

0.232

   

CD4/CD8 ratio

0.528

   

0.417

   

With bulky disease

0.325

   

0.136

   

Rituximab-containing

0.562

   

0.392

   

Chemotherapy regimens

0.459

   

0.355

   
  1. BM, bone marrow; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; * P value was calculated by COX regression and p < 0.05 regarded significant
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us